Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Bioporto - Video med præsentation af Q1-2025 regnskabet

By Claus ThestrupCEO, Sweden
BioPorto

BioPorto annoncerede sit første kvartalsregnskab for 2025 i går, torsdag den 8. maj 2025. Selskabet fastholder sin guidance for året. Salget af ProNephro AKI (NGAL) i USA til pædiatrisk brug forventes fortsat at starte i slutningen af 2025. Til gengæld går indrulleringen af patienter til det kliniske studie ProNephro AKI (NGAL) til voksne over 21 år hurtigere end forventet. Selskabet fastholder målet om at indsende ansøgningen til FDA i slutningen af 2026, og den øgede aktivitet påvirker EBITDA i kvartalet.

Alt dette – samt de mange spørgsmål fra deltagerne på eventet – blev uddybet af CFO Niels Høy Nielsen.

Se hele præsentationen her: Bioporto Q1 event

Disclaimer: HC Andersen Capital modtager betaling fra Bioporto for en Digital IR abonnementsaftale. /Claus Thestrup kl. 07:50, 09/05/2025.

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.